Cambridge Antibody&#39;s Underdog Story
301149
Cambridge Antibody Technology&#39;s (Nasdaq: CATG) legal victory over Abbott Laboratories (NYSE: ABT) shows that a biotech David can triumph over a pharmaceutical Goliath.
22654
A recent study initiated by drug manufacturing company DeCode Genetics of Reykjavik, has come up with startling results. The report was published in âPloS Medicineâ, the on-line journal.
320147
Cancer drug shows exceptional promise as it moves toward FDA review.
761565
A joint biotechnology research venture by two Dutch companies is further underscoring the appeal of the Boston life-science cluster to out-of-state firms, and creating an even tighter real estate market in Cambridge's Kendall Square.
631783
UK biotech company Cambridge Antibody Technology (CAT) has won its court fight for bigger royalties from the sale of arthritis medicine Humira.
704522
Unwanted phase 2 results might not scuttle a promising hepatitis C drug.
40173
Bush won. Thatâs the bad news for stem cell researchers. The good news: California&#39;s Prop. 71 passed. The science is already seeing the election&#39;s fallout.
557373
Cambridge Antibody Technology Group Plc  has won a UK court case to get a bigger slice of sales of a  potential blockbuster arthritis medicine, sending its shares  more than 25 percent higher on Monday.
409638
Promising trials for a hepatitis C treatment bode well for the pharmaceutical.
742015
[Health India]: Washington, Dec 28 : A new study, which has been published in the &quot;The Journal of Experimental Medicine&quot; has indicated that high levels of a blood protein called mannose-binding lectin (MBL) are associated with lower risk of heart attack
325918
At least that&#39;s what NABI Biopharmaceuticals (Nasdaq: NABI) suggests based on the results of a small phase 2 trial with the drug NicVAX that was released yesterday.
752652
AstraZeneca is spending 75 million pounds to take a 20 percent stake in Cambridge Antibody Technology and boost its position in one of the fastest-growing fields of drug research.
327699
Naysayers argue that embryonic stem-cell research deserves no federal funding because it has shown no success. Neither have other heavily funded research programs. By Brandon Keim.
336171
YESTERDAY Close $75.73 Change +$2.22 52-WEEK High $76.90 Low $58.71 Genzyme Corp. of Cambridge said profit jumped tenfold as sales increased for its medicines for rare genetic disorders, some of the world's costliest drugs. The company gained 3 percent in New York trading.
378759
Scientists discover a new protein they believe could help develop much more effective medicines.
252175
&quot;There is clearly a lot of pent-up momentum,&quot; says SourceLabs&#39; Cornelius Willis. &quot;Companies want to get off of proprietary technology, but have been hesitant because of the lack of support.
488705
A new gene therapy causes the bladder to act like a &quot;bioreactor&quot; and secrete an anticancer agent that has proven to fight human tumors.